Human medicines European public assessment report (EPAR): Genvoya, elvitegravir,cobicistat,emtricitabine,tenofovir alafenamide, Date of authorisation: 19/11/2015, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Ixiaro, Japanese encephalitis vaccine (inactivated, adsorbed), Date of authorisation: 31/03/2009, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Gardasil 9, human papillomavirus 9-valent vaccine (recombinant, adsorbed), Date of authorisation: 10/06/2015, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Loargys, pegzilarginase, Date of authorisation: 15/12/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Bimzelx, bimekizumab, Date of authorisation: 20/08/2021, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Teduglutide Viatris, teduglutide, Date of authorisation: 08/01/2026, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Date of authorisation: 16/07/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Latuda, lurasidone, Date of authorisation: 21/03/2014, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Date of authorisation: 09/01/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 11, Status: Authorised